Invest in the Leading Anti-Snoring Solution

Snoring is a massive problem affecting 100M+ people in the US alone. On a global scale, there are almost 600 million snorers in developed countries.  We solve the snoring problem with our patented mouthguards which boasts a 91% success rate proven via an FDA-approved clinical study.

Capturing just 10% of the US market is worth $1B in revenue. Capturing just 0.2% of the snorers in developed countries worldwide is worth $1.2B in revenue. Join the market leaders in stopping snoring as we scale and become the go-to brand for all things sleep.

Opportunity ends in






Minimum Investment


Price Per Share

share price

ınvest now
Sleep Science

Unlocking Better Sleep With a Proven 91% Success Rate

Only one company can guarantee their customers will stop snoring: us. Led by Dr. Jonathan Greenburg, our anti-snoring solutions are backed by science, which is why we have a 91% success rate, more than double our nearest competitor. $55M+ in historical sales shows just how impactful and accepted in the market our solution is. Become a shareholder in the leading anti-snoring company as we accelerate our growth. 


An Investment You Won’t Lose Sleep Over

Led by a seasoned management team, we’ve racked up over $55M in sales to date with our FDA cleared and clinically proven anti-snoring solution. Now we're scaling to new heights, from Amazon to international markets. Reaching just 10% of the US market is worth $1B+ in revenue or just 0.2% of the world market being worth $1.2B in revenue. And you can share in our growth. Let your dreams become reality by joining us as a shareholder.


Historic Growth


 In sales to date




Products sold


Paid for inventory on hand

Current Growth

Past performance is not indicative of future performance.

Approved to sell in the US, Canada, and EU

FDA Cleared

Zyppah Featured On

Click on icons to view videos.

Massive market potential


Only 3% of the USs 100M snorers have sought a solution1


Less than 3% of the global 582M snoring population have sought a solution2

Investor Perks

Approved to sell in the US, Canada, and EU

FDA Cleared

Massive Domestic market potential


Only 3% of the US’s 100M snorers have sought asolution

Massive Global market potential


Less than 3% of the Global 582M snoringpopulation have sought a solution


Snoring Affects Over 100M People in the US Alone

Snoring isn’t just annoying, it’s a major health problem. People who snore get worse sleep, wake up feeling tired, and are at higher risk for a number of health problems.3

Weakened Immune System

Obstructive Sleep Apnea

Sleep Deprivation

Weight Gain

Inability To Lose Weight

Type 2 Diabetes


Heart Disease

High Blood Pressure





Our FDA-Cleared Mouthguard Has a 91% Success Rate

Snoring is caused by the tongue obstructing the airway. We’ve made the only anti-snoring aid that directly stops the tongue from blocking the airway. That’s why we had a 91% success rate in an FDA-approved clinical study (compared to 15% to 45% for our competitors).4

Ready to learn more? Download our pitch deck

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

How ZYPPAH Works


Clinically tested and patented band stabilizes the tongue


Self molded for a custom fit and unsurpassed comfort


Mandibular advancement moves the jaw forward for improved airflow

Snoring is caused by the tongue obstructing the airway. We’ve made the only anti-snoring aid that directly stops the tongue from blocking the airway. That’s why we had a 91% success rate in an FDA-approved clinical study (compared to 15% to 45% for our competitors).


$55M in Sales to Date Is Just the Start

Our 400,000+ customers and $55M in revenue to date prove an anti-snoring device that actually works is in high demand. This is an opportunity to invest in a winning company as we prepare to scale.

$55M+ in sales to date

400,000+ customers

1,000s of 5-star reviews

"Best sleeping product I have ever used. Should have bought more. I have used Zyppah for several years now."


I wear the zyppah every night. My wife no longer wants to smother me with a pillow. I can breath just fine with my zyppah in. I have gotten great results No more snoring for me.


"After 20 years suffering snoring problems, including a surgery without results, this appliance finally solved the problem. Additionally, it replaced my old device for teeth grinding. Great product."


I believe this is the most comfortable and effective appliance on the market. I have tried many different brands and this is the only one that actually works.


I've used the zyppah for 3 years.... am a big fan of this device as is my wife. Zyppah has changed the way that we both sleep. Ive recommended the zyppah to many friends and acquaintances.


Zyppah stopped my snoring on the very first night. I’m not having to roll over every time I wake myself up with a midnight roar, so my husband is sleeping much better, too! I recommend this to everyone I meet who says anything about snoring.


Solving Snoring Is a $1 Billion Opportunity

Our biggest opportunities are ahead of us. With over 100 million snorers in the US alone, a 10% penetration of the market generates over $1B in revenue. Capturing just 0.2% of the snorers in developed countries worldwide is worth $1.2B in revenue.

By joining us as an investor, you can share in our growth as we grow into this market and help people who snore get better sleep, wake up refreshed, and reduce the higher risks for a number of health problems.5

Ready to learn more? Download our pitch deck

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Business Model

A High-Margin Business

As a direct-to-consumer brand, we can keep our costs low and our margins high. We don’t need a large sales team or our own brick-and-mortar stores to scale our brand. Not needing to build an extensive infrastructure is a massive benefit when scaling a company.

Snoring is caused by the tongue obstructing the airway. We’ve made the only anti-snoring aid that directly stops the tongue from blocking the airway. That’s why we had a 91% success rate in an FDA-approved clinical study (compared to 15% to 45% for our competitors).


How Your Investment Helps Us Scale

We aim to leverage our brand as the market leader in anti-snoring devices to expand into more sleep products, including pillows, sleep aids, and even a snoring app. We plan to increase marketing spend in our domestic market while we also expanding internationally

Products coming to market in 3-6 Months

Mouth tape

3-6 months to bring to market


3-6 months to bring to market

Sleep supplement w/ CBD

3-6 months to bring to market

Oxygen desaturation alarm

3-6 months to bring to market

Snoring app

3-6 months to bring to market

Variations of existing products

6 months after full funding

The time frames are expectations, but are subject to change at management's discretion, or abandoned entirely.

Meet the Team

Dr. Greenburg


Dr. Greenburg is a leading name in the snoring & sleep apnea industries.  He is well known in the dental world and the consumer marketplace.  He has treated thousands of patients with snoring & sleep apnea.  He also has significant, successful experience working with the FDA.  

Dr. Greenburg received one of the first degrees in Biomedical Engineering from Syracuse University. This was immediately followed with a DDS degree from New York University. He founded his successful dental practice in Los Angeles, CA in 1982.  He sold the practice in 1991 and entered the corporate arena gaining significant experience with early-stage companies.    

In 2001, he returned to the full-time practice of dentistry and began to study snoring & sleep apnea.  Frustrated that only 10% of the US population was being treated for this devastating condition, he resolved to solve the problem.  

In 2006, he invented a revolutionary new oral/dental appliance for the treatment of snoring & obstructive sleep apnea for which there are a number of patents approved and pending.  These appliances are unique because they are the only true “hybrid” appliances, both advancing the jaw and managing the tongue.  The FDA cleared his appliances in 2012 for sale in the US.

Read Bio +

Close Bio -

Mr. Lawrence Biggs


Lawrence Biggs has founded and served as CEO of both private and publicly traded technology and service companies.  His expertise includes raising capital, mergers and acquisitions, building corporate infrastructure, developing technology-related products, marketing technology products, achieving rapid sales growth, attracting and retaining talented staff, finding and consummating strategic relationships, and communicating to the private and public equity markets.  

Mr. Biggs’ expertise is in early-stage companies, launching products, growing companies, raising capital, and taking companies public.  His involvement immediately prior to Zyppah Inc. was with Vivos Therapeutics, also in the sleep space, where he served as advisor to the CEO and consulted regarding the Company’s capital raise and IPO, including providing and managing a road show for the Company to various investment banks.

The Company ultimately engaged Roth Capital, introduced by Mr. Biggs, which raised $80 million in an IPO and additional offerings.  Mr. Biggs founded and served as CEO of Max Internet Inc., a Company with rapid growth resulting in a public issue on the NASDAQ stock exchange.  The Company manufactured and marketed a computer board utilized for video conferencing and video streaming, earning a patent for the product.  Under Mr. Biggs’ guidance as CEO, Max Internet reached a peak market capitalization of $1.4 billion on the NASDAQ exchange. (NASDAQ: MXIP)  

Mr. Biggs has also served as CEO of additional public companies including MMAX Media (OTCBB: NEPR) a Mixed Marshal Arts television programming Company, and StereoVision (OTCBB: SVSN) a 3D film company.  He also founded the private companies of Rawkin Bliss, Cardio Supply, Pre-Check Health and Spectrum Communications, which granted Mr. Biggs the patent for the Access Phone and was installed across the country in 220,000 hotel rooms.

Read Bio +

Close Bio -

FAQ - About the raise

1. What’s your share price?


2. What is the minimum investment size?


3. What kind of shares are you issuing?


4. How much are you raising?


5. What is the current valuation of the company?


6. Why Should I Invest?

In short, ZYPPAH has a solution to snoring that works twice as well as their nearest competitor, is patented and FDA approved, making it almost impossible to copy or compete against. They’ve proven the market wants this solution with $55M in sales already to 400K customers with less than 7% return rate and thousands of 5 star reviews. They’ve only scratched the surface of their true potential, where capturing just 3% of the American market (100 million people who snore) could generate $100M in sales a year. And more and more people are paying attention to sleep hygiene, making the sleep aid market worth more than $73B.

7. How Will Zyppah Make Money?

They’ve already proven they can with $55M in sales. And as a DTC brand, they don’t have the overhead of many other companies. Their mouth guards boast an 85% gross profit margin.

8. How Do I Know People Will Buy This Solution?

400,000 people have already.

9. Are There More Opportunities Ahead?

Only 3% of America's snorers have even looked for a solution yet. This leaves open 97% of a massive untapped market for ZYPPAH. Plus they have new products they plan to roll out to leverage their brand and capture more of the sleep market. They aim to be the Apple of sleep.

10. Why Didn't A Bigger Company Do This Already?

The brilliance of ZYPPAH lies in its patented design, which effectively addresses the root cause of snoring, the tongue. The unparalleled results are clearly shown in FDA clinical trials that demonstrated a 91% rate of success.  Our competitors can't replicate our product without infringing on our patent rights, and therefore can't achieve the same level of success.

11. How do you plan to use the proceeds from this funding round? 

We plan to increase marketing spend in our domestic market while we also expanding internationally.

12. How do I get a return on my investment?
  1. Investing in startups is risky and there is no guarantee you will get a return on your investment. However, an exit opens up the opportunity where you could convert your shares into cash or a more liquid asset. Exits include going public, getting acquired by a larger company, or our company buying back shares. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits.
  2. You are investing in an early stage revenue company. Success will be measured in progress towards revenue. Future liquidation events could include acquisition or an IPO.
13. What industries are you currently focused on? 

We are focused on combating snoring to provide better sleep for our consumers

14. When will I receive my shares?

Shares will be rewarded after the investment funds clear. This typically takes around 3 weeks after investment. 

15. Are there higher fees if you invest via credit card vs. ACH?

No, costs are the same, regardless of how you invest

16.Will you be paying out dividends to investors?


General FAQ

1. Why invest in startups?

Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.

2. How much can I invest?

Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.

3. How do I calculate my net worth?

To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.

4. What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

5. Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest.

6. What do I need to know about early-stage investing? Are these investments risky?

There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time.  You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.

7. When will I get my investment back?

The Common Stock (the "Shares") of [Zyppah] (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following  scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit.  It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure. 

8. Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.

9. Exceptions to limitations on selling shares during the one-year lockup period:

In the event of death, divorce, or similar circumstance, shares can be transferred to:

  • The company that issued the securities
  • An accredited investor
  • A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
10. What happens if a company does not reach their funding target?

If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.

11. How can I learn more about Zyppah's offering?

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.

12. What if I change my mind about investing?

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email:

13. How do I keep up with how Zyppah is doing?

At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements.  Those should be available 120 days after the fiscal year end.  If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.

14. What relationship does the company have with DealMaker Securities?

Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends. 

Join the Discussion

Loading Comments
Load All Comments